Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in S-Hertogenbosch – page 9

150 clinical trials in S-Hertogenbosch, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
S-Hertogenbosch at a glance
150
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

150 trials in S-Hertogenbosch

Open in trial search

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BOOG Study Center B.V.

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn's Disease Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Amsterdam UMC Stichting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Study on the Safety and Effects of PDC*lung01 Vaccine with Pemetrexed or Pembrolizumab for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:PDC line pharma

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in S-Hertogenbosch

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating innovative combination therapies and treatment approaches. Studies also include investigations into advanced breast cancer treatments and novel therapies for small cell lung cancer.

  • Blood Cancers
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer

Several trials are exploring targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Cardiovascular Studies

Research initiatives examining heart failure prevention and stroke management, including studies on new therapeutic combinations and preventive treatments for cardiovascular events.

  • Heart Failure Prevention
  • Stroke Management
  • Cardiovascular Risk

Focus on developing innovative treatments to reduce cardiovascular mortality and improve patient outcomes.

03 Neurological Disorders

Clinical investigations targeting Alzheimer's disease, evaluating new therapeutic approaches for both mild cognitive impairment and dementia. Studies aim to improve cognitive function and quality of life.

  • Alzheimer's Disease
  • Cognitive Function
  • Dementia Treatment

Trials explore novel drug combinations and treatment strategies for neurodegenerative conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.